About: SARS-CoV infection crosstalk with human host cell noncoding-RNA machinery: An in-silico approach

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV infection crosstalk with human host cell noncoding-RNA machinery: An in-silico approach Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV infection crosstalk with human host cell noncoding-RNA machinery: An in-silico approach
Creator	Biology, Molecular Taheri, Mohammad Alahari, Suresh Mashouri, Ladan Poursheikhani, Arash Vatanmakanian, Mousa Yousefi, Hassan Bahmanpour, Zahra
Source	Elsevier; PMC
abstract	Although 70% of the genome is transcribed to RNA in humans, only ∼2% of these transcripts are translated into proteins. The rest of the transcripts are defined as noncoding RNAs, including Long noncoding RNAs (LncRNAs) and MicroRNAs (miRNAs) that mostly function post-transcriptionally to regulate the gene expression. The outbreak of a novel coronavirus (SARS-CoV) has caused a major public health concern across the globe. The SARS-CoV is the seventh coronavirus that is known to cause human disease. There are currently no promising antiviral drugs with proven efficacy nor are there vaccines for its prevention. As of July 13, 2020, SARS-CoV has been infected more than 13 million cases in more than 213 countries, with an estimated mortality rate of ∼3%. Thus, it is of utmost important priority to develop novel therapies for COVID-19. It is not fully investigated whether noncoding RNAs regulate signaling pathways that SARS-CoV involved in. Hence, computational analysis of the noncoding RNA interactions and determining importance of key regulatory noncoding RNAs in antiviral defense mechanisms will likely be helpful in developing new drugs to attack SARS-CoV infection.. To elucidate this, we utilized bioinformatic approaches to find the interaction network of SARS-CoV/human proteins, miRNAs, and lncRNAs. We found TGF-beta signaling pathway as one of the potential interactive pathways. Furthermore, potential miRNAs/lncRNAs networks that the virus might engage during infection in human host cells have been shown. Altogether, TGF-beta signaling pathway as well as hub miRNAs, and LncRNAs involve during SARS-CoV pathogenesis can be considered as potential therapeutic targets.
has issue date	2020-07-28(xsd:dateTime)
bibo:doi	10.1016/j.biopha.2020.110548
has license	no-cc
sha1sum (hex)	1e84090e7d3054d8e946093fcd7779a80246b631
schema:url	https://doi.org/10.1016/j.biopha.2020.110548
resource representing a document's title	SARS-CoV infection crosstalk with human host cell noncoding-RNA machinery: An in-silico approach
has PubMed Central identifier	PMC7386606
schema:publication	Biomed Pharmacother
resource representing a document's body	covid:1e84090e7d3054d8e946093fcd7779a80246b631#body_text
is schema:about of	named entity 'Although' named entity 'Biomedicine' named entity 'in-silico' named entity 'analysis' named entity 'cell' named entity 'cell' named entity 'infection' named entity 'SARS-CoV' named entity 'human' named entity 'LncRNAs' named entity 'host' named entity 'gene' named entity 'coronavirus' named entity 'Please' named entity 'SMAD4' named entity 'defined' named entity 'machinery' named entity 'Pharmacotherapy' named entity 'SMAD7' named entity 'proteins' named entity 'host' named entity 'Protein-protein interaction' named entity 'doi' named entity 'MicroRNAs' named entity 'doi' named entity 'Homo sapiens' named entity 'noncoding RNAs' named entity 'SARS-CoV' named entity 'miRNA' named entity 'SMAD2' named entity 'LncRNAs' named entity 'gene expression' named entity 'genome' named entity 'SMAD3' named entity 'RNA' named entity 'SARS-CoV' named entity 'interactions' named entity 'SARS-CoV' named entity 'mRNA' named entity 'miRNA' named entity 'mRNAs' named entity 'signaling pathways' named entity 'viral infection' named entity 'miRNA' named entity 'TGF-beta signaling pathway' named entity 'gene' named entity 'signaling pathway' named entity 'noncoding RNAs' named entity 'noncoding RNAs' named entity 'gene' named entity 'infection' named entity 'MiRTarBase' named entity 'Gene Ontology' named entity 'receptor' named entity 'endogenous' named entity 'mRNA' named entity 'molecular interactions' named entity 'miRNAs' named entity 'interaction network' named entity 'lncRNAs' named entity 'infection' named entity 'Gene Set Enrichment Analysis' named entity 'infection' named entity 'mRNAs' named entity 'receptor' named entity 'miRNAs' named entity 'genomes' named entity 'cell signaling' named entity 'miRNA' named entity 'transforming growth factor-beta' named entity 'protein' named entity 'SARS-CoV' named entity 'SARS-CoV' named entity 'GSEA' named entity 'inflammatory' named entity 'noncoding RNAs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software